AbbVie and Mylan announce global settlement

Jul 17, 2018

AbbVie announces a global settlement with Mylan under which Mylan acknowledges Humira® AbbVie’s patents are valid, and Mylan receives a royalty-bearing, non-exclusive global license (excluding Europe) from 31 July 2023.  This date will not be accelerated by entry of Amgen or Samsung Bioepis.

Print Page Mail Article